Pharmacology Flashcards
bioavailability
AUCx/AUCiv
IV drugs bioavailability=1
volume of distribution
Q (dose)/ Cp (plasma concentration)
constant value for a given drug, depends on which compartments
clearance
CL= UV/Cp
Ke (equilibrium of clearance)
CL/Vd
half life equation
- 7 Vd/ CL or
0. 7/Ke
maintenance dose
MD= (Cp *CL *t)/ F
t= dosing interval
loading dose
LD= (Cp*Vd)/ F
acetazolamide moa
carbonic anhydrase inhibition, blocks generation of H+ in cell which lowers Na reabsorption
acetazolamide toxicity
met acidosis (also blocks bicarb reabsorption)
hypokalemia- high Na and water delivery to distal segments
loop diuretic examples and moa
furosemide. torsemide, bumetanide, etharcrynic acid
inhibit NKCC on loop of henle- reduce Na reabsorption
loop toxicities (4)
hypokalemia- more Na and water delivery, RAAS activation from volume loss (more potent w/ loop)
met alkalosis- aldo promotes H+ secretion along w/ K+
hypocalcemia/hypercalciuria- less Na thru NKCC means less K is secreted thru ROMK, loss of the lumen positivity that normally drives Ca reabsorption paracellularly
-can drive formation of kidney stones, nephrolithiasis
hyperuricemia/gout- compete w/ same proteins for secretion as urea (OAT1, 2, 4, 10)
thiazide examples
HTCZ, chlortalidone, metolazone
thiazide moa
NCC block at the DCT, less potent than loop diuretics
thiazide toxicity (5)
hypokalemia
hypercalcemia- reduciton in intracellular Na causes more activity at basolateral Na/Ca exchanger (moving Ca into interstitium) which stimulates Ca uptake from urine
met alkalosis- RAAS activation, less so than loops
hyperuricemia and gout- competition w/ urate secretion
hyperglycemia/DM- volume reduction causes sympathetic stim, less glucose uptake and a higher serum glucose
-loss of K reduces insulin stimulus, raising glucose
distinguish 2 moas of K sparing drugs
aldo receptor inhibs- sprionolactone and eplerenone
ENaC inhibs- amiloride, tramterene
both cause lack of ENaC fn